SEARCH:   Advanced

Blood, 1 September 2005, Vol. 106, No. 5, pp. 1831-1838. Prepublished online as a Blood First Edition Paper on May 24, 2005; DOI 10.1182/blood-2004-10-3898. This Article Full Text (PDF) All Versions of this Article: 2004-10-3898v1 106/5/1831    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ruiz-Ballesteros, E. Articles by Piris, M. A Search for Related Content PubMed PubMed Citation Articles by Ruiz-Ballesteros, E. Articles by Piris, M. A Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted October 8, 2004 Accepted May 11, 2005 Splenic marginal zone lymphoma. Proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis Elena Ruiz-Ballesteros, Manuela Mollejo, Antonia Rodriguez, Francisca I Camacho, Patrocinio Algara, Nerea Martinez, Marina Pollan, Abel Sanchez-Aguilera, Javier Menarguez, Elias Campo, Pedro Martinez, Marisol Mateo, and Miguel A Piris* Department of Genetics and Pathology, Hospital Virgen de la Salud (HVS), Toledo, Spain Molecular Pathology Program, Centro Nacional de Investigaciones Oncologicas (CNIO), Madrid, Spain Cancer Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain Department of Pathology, Hospital General Universitario Gregorio Maranon, Madrid, Spain Department of Pathology, Hospital Clinic, Barcelona, Spain * Corresponding author; email: mapiris{at}cnio.es. Splenic marginal zone lymphoma (SMZL) is a newly recognized lymphoma type whose precise molecular pathogenesis is still essentially unknown. This hampers differential diagnosis with other small B-cell malignancies. With the aim of characterizing this tumor more comprehensively, and of identifying new diagnostic and prognostic markers, we performed cDNA microarray expression profiling and tissue microarray (TMA) immunohistochemical studies in a relatively large series of 44 SMZLs. The results were related to IgVH mutational status and clinical outcome. SMZLs display a largely homogenous signature, implying the existence of a single molecular entity. Of the genes deregulated in SMZLs, special mention may be made of the genes involved in BCR signaling, TNF signaling and NF-B activation, such as SYK, BTK, BIRC3, TRAF3 and LTB. Other genes observed were SELL and LPXN, which were highly expressed in spleen, and lymphoma oncogenes, such as ARHH and TCL1. In contrast, the genes CAV1, CAV2 and GNG11 located in 7q31, a commonly deleted area, were downregulated in the entire series. A comparison with the genes comprising the signature of other small B-cell lymphomas identified three genes whose expression distinguishes SMZL, namely ILF1, Senataxin and CD40. Shorter survival was associated with CD38 expression, naive IgVH genes and the expression of a set of NF-B pathway genes, including TRAF5, REL and PKC-alpha. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Montes-Moreno, G. Roncador, L. Maestre, N. Martinez, L. Sanchez-Verde, F. I. Camacho, J. Cannata, J. L. Martinez-Torrecuadrada, Y. Shen, W. C. Chan, et al. Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas Blood, January 1, 2008; 111(1): 351 - 358. [Abstract] [Full Text] [PDF] L. Leseux, S. M. Hamdi, T. al Saati, F. Capilla, C. Recher, G. Laurent, and C. Bezombes Syk-dependent mTOR activation in follicular lymphoma cells Blood, December 15, 2006; 108(13): 4156 - 4162. [Abstract] [Full Text] [PDF] A. Sanchez-Aguilera, C. Montalban, P. de la Cueva, L. Sanchez-Verde, M. M. Morente, M. Garcia-Cosio, J. Garcia-Larana, C. Bellas, M. Provencio, V. Romagosa, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma Blood, July 15, 2006; 108(2): 662 - 668. [Abstract] [Full Text] [PDF] L. Arcaini, M. Lazzarino, N. Colombo, S. Burcheri, E. Boveri, M. Paulli, E. Morra, M. Gambacorta, S. Cortelazzo, A. Tucci, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use Blood, June 15, 2006; 107(12): 4643 - 4649. [Abstract] [Full Text] [PDF] S. Ek, U. Andreasson, S. Hober, C. Kampf, F. Ponten, M. Uhlen, H. Merz, and C. A. K. Borrebaeck From Gene Expression Analysis to Tissue Microarrays: A Rational Approach to Identify Therapeutic and Diagnostic Targets in Lymphoid Malignancies Mol. Cell. Proteomics, June 1, 2006; 5(6): 1072 - 1081. [Abstract] [Full Text] [PDF] R. D. Gascoyne Hematopathology Approaches to Diagnosis and Prognosis of Indolent B-Cell Lymphomas Hematology, January 1, 2005; 2005(1): 299 - 306. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020